Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TB or not TB: treat to see.
van Daele PL, Bakker M, van Hagen PM, Baarsma GS, Kuijpers RW. van Daele PL, et al. Among authors: van hagen pm. Med J Aust. 2006 Aug 7;185(3):178-9. doi: 10.5694/j.1326-5377.2006.tb00515.x. Med J Aust. 2006. PMID: 16893366 No abstract available.
Adalimumab: a new modality for Behçet's disease?
van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. van Laar JA, et al. Among authors: van hagen pm, van daele pl. Ann Rheum Dis. 2007 Apr;66(4):565-6. doi: 10.1136/ard.2006.064279. Epub 2006 Nov 23. Ann Rheum Dis. 2007. PMID: 17124248 Free PMC article. No abstract available.
Cytokines in uveitis.
van Laar JA, van Hagen PM. van Laar JA, et al. Among authors: van hagen pm. Clin Med Res. 2006 Dec;4(4):248-9. doi: 10.3121/cmr.4.4.248. Clin Med Res. 2006. PMID: 17210973 Free PMC article. No abstract available.
Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis.
Missotten T, van Laar JA, van der Loos TL, van Daele PL, Kuijpers RW, Baarsma GS, van Hagen PM. Missotten T, et al. Among authors: van hagen pm, van laar ja, van daele pl, van der loos tl. Am J Ophthalmol. 2007 Dec;144(6):838-843. doi: 10.1016/j.ajo.2007.07.039. Epub 2007 Oct 4. Am J Ophthalmol. 2007. PMID: 17916316
Is imatinib mesylate a promising drug in systemic sclerosis?
van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM. van Daele PL, et al. Among authors: van hagen pm, van laar ja, van hal pt. Arthritis Rheum. 2008 Aug;58(8):2549-52. doi: 10.1002/art.23648. Arthritis Rheum. 2008. PMID: 18668570 Free article.
Low level IGF-1 and common variable immune deficiency: an unusual combination.
van Bilsen K, Driessen GJ, de Paus RA, van de Vosse E, van Lom K, van Zelm MC, Lam KH, Hartwig NG, Baarsma GS, van de Burg M, van Hagen PM. van Bilsen K, et al. Among authors: van hagen pm, van lom k, van de burg m, van de vosse e, van zelm mc. Neth J Med. 2008 Oct;66(9):368-72. Neth J Med. 2008. PMID: 18931397 Free article.
Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PL, van Hagen PM, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA. van Steensel L, et al. Among authors: van den bosch wa, van hagen pm, van daele pl. Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3091-8. doi: 10.1167/iovs.08-2443. Epub 2009 Feb 21. Invest Ophthalmol Vis Sci. 2009. PMID: 19234339
266 results